skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders

Authors:
; ; ORCiD logo; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; more »; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; « less
Publication Date:
Research Org.:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Org.:
INDUSTRY
OSTI Identifier:
1399122
Resource Type:
Journal Article
Resource Relation:
Journal Name: Journal of Medicinal Chemistry; Journal Volume: 60; Journal Issue: 12
Country of Publication:
United States
Language:
ENGLISH

Citation Formats

Liu, Qingjie, Shi, Qing, Marcoux, David, Batt, Douglas G., Cornelius, Lyndon, Qin, Lan-Ying, Ruan, Zheming, Neels, James, Beaudoin-Bertrand, Myra, Srivastava, Anurag S., Li, Ling, Cherney, Robert J., Gong, Hua, Watterson, Scott H., Weigelt, Carolyn, Gillooly, Kathleen M., McIntyre, Kim W., Xie, Jenny H., Obermeier, Mary T., Fura, Aberra, Sleczka, Bogdan, Stefanski, Kevin, Fancher, R. M., Padmanabhan, Shweta, RP, Thatipamula, Kundu, Ipsit, Rajareddy, Kallem, Smith, Rodney, Hennan, James K., Xing, Dezhi, Fan, Jingsong, Levesque, Paul C., Ruan, Qian, Pitt, Sidney, Zhang, Rosemary, Pedicord, Donna, Pan, Jie, Yarde, Melissa, Lu, Hao, Lippy, Jonathan, Goldstine, Christine, Skala, Stacey, Rampulla, Richard A., Mathur, Arvind, Gupta, Anuradha, Arunachalam, Pirama Nayagam, Sack, John S., Muckelbauer, Jodi K., Cvijic, Mary Ellen, Salter-Cid, Luisa M., Bhide, Rajeev S., Poss, Michael A., Hynes, John, Carter, Percy H., Macor, John E., Ruepp, Stefan, Schieven, Gary L., and Tino, Joseph A. Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders. United States: N. p., 2017. Web. doi:10.1021/acs.jmedchem.7b00618.
Liu, Qingjie, Shi, Qing, Marcoux, David, Batt, Douglas G., Cornelius, Lyndon, Qin, Lan-Ying, Ruan, Zheming, Neels, James, Beaudoin-Bertrand, Myra, Srivastava, Anurag S., Li, Ling, Cherney, Robert J., Gong, Hua, Watterson, Scott H., Weigelt, Carolyn, Gillooly, Kathleen M., McIntyre, Kim W., Xie, Jenny H., Obermeier, Mary T., Fura, Aberra, Sleczka, Bogdan, Stefanski, Kevin, Fancher, R. M., Padmanabhan, Shweta, RP, Thatipamula, Kundu, Ipsit, Rajareddy, Kallem, Smith, Rodney, Hennan, James K., Xing, Dezhi, Fan, Jingsong, Levesque, Paul C., Ruan, Qian, Pitt, Sidney, Zhang, Rosemary, Pedicord, Donna, Pan, Jie, Yarde, Melissa, Lu, Hao, Lippy, Jonathan, Goldstine, Christine, Skala, Stacey, Rampulla, Richard A., Mathur, Arvind, Gupta, Anuradha, Arunachalam, Pirama Nayagam, Sack, John S., Muckelbauer, Jodi K., Cvijic, Mary Ellen, Salter-Cid, Luisa M., Bhide, Rajeev S., Poss, Michael A., Hynes, John, Carter, Percy H., Macor, John E., Ruepp, Stefan, Schieven, Gary L., & Tino, Joseph A. Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders. United States. doi:10.1021/acs.jmedchem.7b00618.
Liu, Qingjie, Shi, Qing, Marcoux, David, Batt, Douglas G., Cornelius, Lyndon, Qin, Lan-Ying, Ruan, Zheming, Neels, James, Beaudoin-Bertrand, Myra, Srivastava, Anurag S., Li, Ling, Cherney, Robert J., Gong, Hua, Watterson, Scott H., Weigelt, Carolyn, Gillooly, Kathleen M., McIntyre, Kim W., Xie, Jenny H., Obermeier, Mary T., Fura, Aberra, Sleczka, Bogdan, Stefanski, Kevin, Fancher, R. M., Padmanabhan, Shweta, RP, Thatipamula, Kundu, Ipsit, Rajareddy, Kallem, Smith, Rodney, Hennan, James K., Xing, Dezhi, Fan, Jingsong, Levesque, Paul C., Ruan, Qian, Pitt, Sidney, Zhang, Rosemary, Pedicord, Donna, Pan, Jie, Yarde, Melissa, Lu, Hao, Lippy, Jonathan, Goldstine, Christine, Skala, Stacey, Rampulla, Richard A., Mathur, Arvind, Gupta, Anuradha, Arunachalam, Pirama Nayagam, Sack, John S., Muckelbauer, Jodi K., Cvijic, Mary Ellen, Salter-Cid, Luisa M., Bhide, Rajeev S., Poss, Michael A., Hynes, John, Carter, Percy H., Macor, John E., Ruepp, Stefan, Schieven, Gary L., and Tino, Joseph A. 2017. "Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders". United States. doi:10.1021/acs.jmedchem.7b00618.
@article{osti_1399122,
title = {Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders},
author = {Liu, Qingjie and Shi, Qing and Marcoux, David and Batt, Douglas G. and Cornelius, Lyndon and Qin, Lan-Ying and Ruan, Zheming and Neels, James and Beaudoin-Bertrand, Myra and Srivastava, Anurag S. and Li, Ling and Cherney, Robert J. and Gong, Hua and Watterson, Scott H. and Weigelt, Carolyn and Gillooly, Kathleen M. and McIntyre, Kim W. and Xie, Jenny H. and Obermeier, Mary T. and Fura, Aberra and Sleczka, Bogdan and Stefanski, Kevin and Fancher, R. M. and Padmanabhan, Shweta and RP, Thatipamula and Kundu, Ipsit and Rajareddy, Kallem and Smith, Rodney and Hennan, James K. and Xing, Dezhi and Fan, Jingsong and Levesque, Paul C. and Ruan, Qian and Pitt, Sidney and Zhang, Rosemary and Pedicord, Donna and Pan, Jie and Yarde, Melissa and Lu, Hao and Lippy, Jonathan and Goldstine, Christine and Skala, Stacey and Rampulla, Richard A. and Mathur, Arvind and Gupta, Anuradha and Arunachalam, Pirama Nayagam and Sack, John S. and Muckelbauer, Jodi K. and Cvijic, Mary Ellen and Salter-Cid, Luisa M. and Bhide, Rajeev S. and Poss, Michael A. and Hynes, John and Carter, Percy H. and Macor, John E. and Ruepp, Stefan and Schieven, Gary L. and Tino, Joseph A.},
abstractNote = {},
doi = {10.1021/acs.jmedchem.7b00618},
journal = {Journal of Medicinal Chemistry},
number = 12,
volume = 60,
place = {United States},
year = 2017,
month = 6
}
  • SHP2 is a nonreceptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also purportedly plays an important role in the programmed cell death pathway (PD-1/PD-L1). Because it is an oncoprotein associated with multiple cancer-related diseases, as well as a potential immunomodulator, controlling SHP2 activity is of significant therapeutic interest. Recently in our laboratories, a small molecule inhibitor of SHP2 was identified as an allosteric modulator that stabilizes the autoinhibited conformation of SHP2. A high throughput screen was performed to identify progressable chemical matter, and X-ray crystallography revealedmore » the location of binding in a previously undisclosed allosteric binding pocket. Structure-based drug design was employed to optimize for SHP2 inhibition, and several new protein–ligand interactions were characterized. These studies culminated in the discovery of 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine (SHP099, 1), a potent, selective, orally bioavailable, and efficacious SHP2 inhibitor.« less
  • Efforts to identify a suitable follow-on compound to razaxaban (compound 4) focused on modification of the carboxamido linker to eliminate potential in vivo hydrolysis to a primary aniline. Cyclization of the carboxamido linker to the novel bicyclic tetrahydropyrazolopyridinone scaffold retained the potent fXa binding activity. Exceptional potency of the series prompted an investigation of the neutral P{sub 1} moieties that resulted in the identification of the p-methoxyphenyl P{sub 1}, which retained factor Xa binding affinity and good oral bioavailability. Further optimization of the C-3 pyrazole position and replacement of the terminal P{sub 4} ring with a neutral heterocycle culminated inmore » the discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, compound 40). Compound 40 exhibits a high degree of fXa potency, selectivity, and efficacy and has an improved pharmacokinetic profile relative to 4.« less
  • RAS oncogenes have been implicated in >30% of human cancers, all representing high unmet medical need. The exquisite dependency on CRAF kinase in KRAS mutant tumors has been established in genetically engineered mouse models and human tumor cells. To date, many small molecule approaches are under investigation to target CRAF, yet kinase-selective and cellular potent inhibitors remain challenging to identify. Herein, we describe 14 (RAF709) [Aversa, Biaryl amide compounds as kinase inhibitors and their preparation. WO 2014151616, 2014], a selective B/C RAF inhibitor, which was developed through a hypothesis-driven approach focusing on drug-like properties. A key challenge encountered in themore » medicinal chemistry campaign was maintaining a balance between good solubility and potent cellular activity (suppression of pMEK and proliferation) in KRAS mutant tumor cell lines. We investigated the small molecule crystal structure of lead molecule 7 and hypothesized that disruption of the crystal packing would improve solubility, which led to a change from N-methylpyridone to a tetrahydropyranyl oxy-pyridine derivative. 14 proved to be soluble, kinase selective, and efficacious in a KRAS mutant xenograft model.« less